Erythromycin bioactivity is stable in ophthalmic ointment used for prophylaxis of neonatal gonococcal conjunctivitis

Antimicrob Agents Chemother. 1987 Jun;31(6):954-5. doi: 10.1128/AAC.31.6.954.

Abstract

Erythromycin ophthalmic ointment (E. Fougera & Co., Melville, N.Y.) and erythromycin gluceptate standards prepared in ointment base were stored at room temperature and heated at temperatures up to 45 degrees C for as long as 6 h before being assayed for bioactivity. We were unable to detect any significant loss of antibiotic bioactivity.

MeSH terms

  • Conjunctivitis, Bacterial / prevention & control*
  • Drug Packaging
  • Drug Stability
  • Erythromycin / administration & dosage
  • Erythromycin / pharmacology*
  • Erythromycin / therapeutic use
  • Gonorrhea / prevention & control*
  • Humans
  • Infant, Newborn
  • Microbial Sensitivity Tests
  • Ointments
  • Ophthalmic Solutions
  • Syringes

Substances

  • Ointments
  • Ophthalmic Solutions
  • Erythromycin